Print

Amarin Corporation PLC (AMRN) Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs  
1/22/2013 9:12:24 AM

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed (available at: http://www.ncbi.nlm.nih.gov/pubmed/23325450) and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February 2013.
//-->